Open AccessA systematic review and meta-analysis of Penner serotype prevalence of Campylobacter jejuni in low- and middle-income countries
Author(s) -
Tegan N. Clarke,
Megan A. Schilling,
Luca A. Melendez,
Sandra D. Isidean,
Chad K. Porter,
Frédéric Poly
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0251039
Subject(s) - campylobacter jejuni , serotype , biology , meta analysis , microbiology and biotechnology , virology , medicine , bacteria , genetics
While Campylobacter jejuni is a leading foodborne bacterial pathogen worldwide, it poses a particular risk to susceptible populations in low- and middle-income countries (LMICs). A capsule-conjugate vaccine approach has been proposed as a potential solution, but little information exists on circulating C . jejuni capsule types in LMICs. The capsule is the major serodeterminant of the Penner typing scheme, which is based on serum recognition of Campylobacter heat-stable antigens. We conducted a systematic review and meta-analysis to estimate the distribution of Penner serotypes associated with C . jejuni enteritis in LMICs. Vaccine coverage assessments for hypothetical regional and global C . jejuni vaccines were also estimated. Methods A systematic review of the literature published from 1980 to 2019 was performed using PubMed, Scopus, and Web of Science databases. Articles were assessed for eligibility and data were abstracted. Pooled C . jejuni serotype prevalence in LMICs was estimated by region and globally using random-effects models. Results A total of 36 studies were included, capturing 4,434 isolates from LMICs. Fifteen serotypes were present in a sufficient number of studies to be included in analyses. Among these, HS4c was the most common serotype globally (12.6%), though leading capsule types varied among regions. HS2, HS3c, HS4c, HS5/31, HS8/17, and HS10 were all among the 10 most common region-specific serotypes. Conclusions The results of this review suggest that an octavalent vaccine could provide up to 66.9% coverage of typable strains worldwide, and 56.8–69.0% regionally. This review also highlights the paucity of available data on capsules in LMICs; more testing is needed to inform vaccine development efforts.